CryoPort (NASDAQ:CYRX) Director Sells $115,584.30 in Stock

CryoPort, Inc. (NASDAQ:CYRX) Director Ramkumar Mandalam sold 11,570 shares of the business’s stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total transaction of $115,584.30. Following the completion of the sale, the director owned 80,758 shares in the company, valued at approximately $806,772.42. This trade represents a 12.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

CryoPort Price Performance

Shares of NASDAQ:CYRX traded down $0.24 during trading hours on Friday, hitting $9.40. 655,383 shares of the company’s stock traded hands, compared to its average volume of 576,184. The company’s fifty day simple moving average is $9.43 and its two-hundred day simple moving average is $8.46. The company has a market cap of $470.65 million, a price-to-earnings ratio of 8.03 and a beta of 1.51. The company has a debt-to-equity ratio of 0.40, a quick ratio of 15.01 and a current ratio of 15.77. CryoPort, Inc. has a 52 week low of $4.58 and a 52 week high of $11.44.

CryoPort (NASDAQ:CYRX) last released its earnings results on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. The business had revenue of $44.23 million during the quarter, compared to analyst estimates of $41.22 million. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%. As a group, equities analysts anticipate that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Trading of CryoPort

Hedge funds have recently made changes to their positions in the stock. Mak Capital One LLC acquired a new stake in shares of CryoPort during the third quarter worth approximately $7,756,000. UBS Group AG lifted its position in CryoPort by 112.7% in the 3rd quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock worth $12,623,000 after buying an additional 705,649 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in shares of CryoPort during the 2nd quarter valued at $4,084,000. Millennium Management LLC grew its holdings in shares of CryoPort by 18.5% during the 3rd quarter. Millennium Management LLC now owns 2,620,906 shares of the company’s stock valued at $24,846,000 after acquiring an additional 408,335 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of CryoPort by 37.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock worth $14,208,000 after acquiring an additional 408,263 shares during the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CYRX. Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a report on Monday. UBS Group increased their price target on CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a research report on Wednesday, November 5th. BTIG Research boosted their price objective on CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Finally, Needham & Company LLC upped their price objective on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $12.83.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.